GlobeNewswire by notified

Clariant presents Integrated Report 2021

Share
  • Clariant publishes Integrated Report 2021, detailing thecompany’s financial and
    non-financial business activities for the year
  • The report illustrates Clariant’s new purpose-led strategy as summarized by the statement Greater chemistry between people and planet
  • Annual General Meeting (AGM) agenda published

MUTTENZ,JUNE 2, 2022

Clariant, a focused, sustainable, and innovative specialty chemical company, today published its Integrated Report 2021, which presents a transparent and concise account of all the company’s financial and non-financial business activities for the year.

The Integrated Report is a vital tool for the company to measure progress, hold itself accountable to set targets and for stakeholders to gain deeper insight into key areas of the business. It contains the ‘Business Report’, the ‘Financial Report’, the ‘Corporate Governance Report’, the ‘Compensation Report’ and the ‘Review on Performance, People, and Planet’. Access it here: reports.clariant.com

The sustainability agenda being at the heart of all of Clariant’s activities, reporting in 2021 centers not only on disclosing important metrics to measure how the business impacts the environment but also how the company aims to contribute in the battle against climate change with valuable sustainability innovations.

“Our strong commitment to sustainability is duly reflected in our purpose statement ‘Greater chemistry – between people and planet.’ Pursuing this purpose is a collaborative, interconnected and ongoing process that takes into account the needs of all Clariant stakeholder groups,” said Günter von Au, Chairman of the Board of Directors. “Our Integrated Report is the perfect vehicle to capture and illustrate the many facets of those activities.”

Clariant looks back on a year of record profitability, which demonstrates how the changes of the past years have come to fruition to create a resilient, lean and future orientated company that is best placed to generate value from the next megatrends in diverse business sectors. At the Annual General Meeting (AGM) on 24 June 2022, the Board of Directors will present the Integrated Report detailing the business developments for the year 2021 to the shareholders for approval.

Today, Clariant also published all further agenda items for the upcoming AGM (link to website). They include:

  • Reelection of Günter von Au as Chairman of the Board of Directors
  • The nomination of three new candidates to the Board of Directors: Ahmed Mohamed Alumar, Saudi Arabian Citizen; Roberto César Gualdoni, German and Italian Citizen; Naveena Shastri, US Citizen. These candidates nominated by SABIC International Holdings B.V. are considered to be independent in accordance Swiss Code of Best Practice for Corporate Governance.
    In case of election of the new members and the reelection of the current members, the board diversity increases to 36 % female Board members.
  • A distribution of CHF 0.40 per share. This distribution represents an attractive pay-out ratio of 49 % of continuing operations earnings per share (EPS: CHF 0.81) and is proposed to be made through capital reduction by way of par value reduction.
  • After more than two decades with a trusted partner, changing statutory auditor from 2022 to allow for a fresh start following the conclusion of the investigation into accounting issues. KPMG will be submitted for the role.

This year’s AGM will again be held virtually. Shareholders may exclusively be represented and have their voting rights exercised by the independent proxy.

CORPORATE MEDIA RELATIONS



Jochen Dubiel
Phone +41 61 469 63 63
jochen.dubiel@clariant.com




Anne Maier
Phone +41 61 469 63 63
anne.maier@clariant.com



Ellese Golder
Phone +41 61 469 63 63
ellese.golder@clariant.com

INVESTOR RELATIONS



Andreas Schwarzwälder
Phone +41 61 469 63 73
andreas.schwarzwaelder@clariant.com



Maria Ivek
Phone +41 61 469 63 73
maria.ivek@clariant.com



Alexander Kamb
Phone +41 61 469 63 73
alexander.kamb@clariant.com
Follow us on Twitter, Facebook, LinkedIn, Instagram.



This media release contains certain statements that are neither reported financial results nor other historical information. This document also includes forward-looking statements. Because these forward-looking statements are subject to risks and uncertainties, actual future results may differ materially from those expressed in or implied by the statements. Many of these risks and uncertainties relate to factors that are beyond Clariant’s ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of governmental regulators and other risk factors such as: the timing and strength of new product offerings; pricing strategies of competitors; the Company’s ability to continue to receive adequate products from its vendors on acceptable terms, or at all, and to continue to obtain sufficient financing to meet its liquidity needs; and changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions, including currency fluctuations, inflation and consumer confidence, on a global, regional or national basis. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. Clariant does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of these materials.



www.clariant.com





Clariant is a focused, sustainable, and innovative specialty chemical company based in Muttenz, near Basel/Switzerland. On 31 December 2021, the company employed a total workforce of 13 374. In the financial year 2021, Clariant recorded sales of CHF 4.372 billion for its continuing businesses. The company reports in three business areas: Care Chemicals, Catalysis and Natural Resources. Clariant’s corporate strategy is led by the overarching purpose of ‘Greater chemistry – between people and planet’ and reflects the importance of connecting customer focus, innovation, sustainability, and people.

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ONWARD® Medical Reports Full Year 2023 Financial and Operating Results and Shares 2024 Highlights Year-to-Date25.4.2024 07:30:00 CEST | Press release

Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital Announced positive top-line results from Up-LIFT pivotal study Forged partnership to provide rapid access to US Veterans Health Administration Continued to pioneer brain-computer interface therapies for SCI EINDHOVEN, The Netherlands, April 25, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces its Full Year 2023 Financial and Operating Results. “In 2023, we made substantial progress against our objectives and laid the foundation to bring our ARC-EX System to the US market later this year,” said Dave Marver, CEO of ONWARD Medical. “We are off to a strong start again in 2024, raising EUR 20M in equity capital and submitting our De Novo application to the FDA for the ARC-EX System.” Full Year 2

Press Release: Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance25.4.2024 07:30:00 CEST | Press release

Sanofi Q1: robust 7% sales growth driven by launches, underpins full-year guidance Paris, April 25, 2024 Sales growth of 6.7% at CER and business EPS(1) of €1.78 Dupixent sales up 24.9% to €2,835 million, on target to deliver ~€13bn in 2024Pharma launches up 90.5% to €606 million, led by Nexviazyme and ALTUVIIIOVaccines sales up 5.6%, boosted by BeyfortusConsumer Healthcare (CHC) up 9.0%, benefiting from the Qunol acquisition in Physical and Mental Wellness and strong Digestive Wellness performanceR&D expenses grew 11.8%, reflecting strategic shift of resources into developmentSG&A expenses grew 2.9%, less than sales growthBusiness EPS(1) of €1.78, down 17.6% reported and 7.4% at CERIFRS EPS of €0.91, down 43.1% reported R&D transformation advanced further Three regulatory approvals: new Dupixent indications in the US and Japan and Beyfortus in JapanPositive phase 3 results for rilzabrutinib in immune thrombocytopenia, a rare diseaseReaffirming increasing pipeline news flow over 2024-2

Huhtamäki Oyj’s Interim Report January 1–March 31, 2024: Improved operational profitability25.4.2024 07:30:00 CEST | Press release

HUHTAMÄKI OYJ INTERIM REPORT 25.4.2024 AT 8:30 EEST Q1 2024 in brief Net sales decreased 4% to EUR 1,004 million (EUR 1,047 million)Comparable net sales growth was -2% at Group levelReported EBIT was EUR 78 million (EUR 87 million); adjusted EBIT was EUR 99 million (EUR 92 million)Reported EPS was EUR 0.35 (EUR 0.47); adjusted EPS was EUR 0.55 (EUR 0.51)The impact of currency movements was EUR -17 million on the Group's net sales and EUR -2 million on EBIT Key figures EUR million Q1 2024 Q1 2023 Change 2023 Net sales 1,003.9 1,047.1 -4% 4,168.9 Comparable net sales growth -2% 2% -2% Adjusted EBITDA1 149.0 140.5 6% 590.1 Margin1 14.8% 13.4% 14.2% EBITDA 137.7 138.1 -0% 621.2 Adjusted EBIT2 98.8 92.1 7% 392.6 Margin2 9.8% 8.8% 9.4% EBIT 77.6 87.4 -11% 380.9 Adjusted EPS, EUR3 0.55 0.51 7% 2.32 EPS, EUR 0.35 0.47 -27% 1.97 Adjusted ROI2 11.5% 10.7% 11.2% Adjusted ROE3 13.3% 13.7% 13.2% ROI 10.7% 11.0% 10.9% ROE 11.0% 14.3% 11.8% Capital expenditure 36.6 65.2 -44% 318.7 Free Cash Flow 38.2

TRAINERS’ HOUSE GROUP INTERIM REPORT 1 JANUARY – 31 MARCH 202425.4.2024 07:30:00 CEST | Press release

TRAINERS' HOUSE GROUP, STOCK EXCHANGE RELEASE, 25 APRIL 2024 at 8:30 January-March 2024 in brief net sales EUR 2.3 million (EUR 2.8 million), change of -18.3 % compared to the corresponding period of the previous yearoperating result EUR 0.2 million (EUR 0.4 million), 7.3 % of net sales (14.5 %)cash flow from operations EUR 0.2 million (EUR 0.3 million)earnings per share EUR 0.08 (EUR 0.19) Key figures at the end of first quarter of 2024 cash and cash equivalents EUR 1.3 million (EUR 2.5 million)interest-bearing liabilities of EUR 0.8 million (EUR 0.4 million) and interest-bearing net debt of EUR -0.5 million (EUR -2.1 million).equity ratio 64.3 % (59.5 %) OUTLOOK FOR 2024 The company estimates the operating profit for 2024 to be negative. CEO ARTO HEIMONEN In the review period, acquiring new orders was challenging. The demand for services connected to overall well-being, mental growth and creating of meanings is growing. The sales of the company's personal training products strengthen

Flow Traders Q1 2024 Trading Update25.4.2024 07:30:00 CEST | Press release

Flow Traders Q1 2024 Trading Update Amsterdam, the Netherlands - Flow Traders Ltd. (Euronext: FLOW) announces its unaudited Q1 2024 trading update. Highlights Flow Traders recorded Net Trading Income of €127.1m and Total Income of €129.6m in Q124, compared to €72.7m and €74.3m, respectively, in Q423, and €110.5m for both in Q123. Flow Traders’ Value Traded increased 7% in Q124 when compared to last quarter and was flat when compared to the same period last year.Total Operating Expenses were €68.5m in Q124, compared to €62.5m in Q423 and €70.3m in Q123, with Fixed Operating Expenses of €43.6m, compared to €40.4m in Q423 and €43.9m in Q123.EBITDA was €61.1m in Q124, generating an EBITDA margin of 47%, compared to €11.8m and 16% in Q423 and €40.2m and 36% in Q123. Net Profit was €45.9m in Q124, yielding a basic EPS of €1.06, compared to €6.4m of Net Profit and €0.15 of basic EPS in Q423 and €27.7m and €0.64 in Q123. Trading capital stood at €609m at the end of Q124 and generated a 52% ret

HiddenA line styled icon from Orion Icon Library.Eye